KBC Group’s Novavax NVAX Stock Holding History

KBC Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45K	Hold	4,746	–	–	﹤0.01%	1736
2026 Q1	$39K	Buy	4,746 +1,229	+35%	+$11.1K	﹤0.01%	1730
2025 Q4	$24K	Hold	3,517	–	–	﹤0.01%	1723
2025 Q3	$30K	Hold	3,517	–	–	﹤0.01%	1721
2025 Q2	$22K	Sell	3,517 -4,437	-56%	-$29.4K	﹤0.01%	1705
2025 Q1	$51K	Hold	7,954	–	–	﹤0.01%	1786
2024 Q4	$64K	Buy	7,954 +3,917	+97%	+$37.8K	﹤0.01%	1766
2024 Q3	$51K	Hold	4,037	–	–	﹤0.01%	1701
2024 Q2	$51K	Buy	+4,037	New	+$40.6K	﹤0.01%	1601
2023 Q4	–	Sell	-1,798	Closed	-$13K	–	1897
2023 Q3	$13K	Buy	+1,798	New	+$14.4K	﹤0.01%	1910
2022 Q4	–	Sell	-736	Closed	-$13K	–	1544
2022 Q3	$13K	Hold	736	–	–	﹤0.01%	1539
2022 Q2	$38K	Sell	736 -2,520	-77%	-$131K	﹤0.01%	1467
2022 Q1	$240K	Hold	3,256	–	–	﹤0.01%	998
2021 Q4	$466K	Sell	3,256 -2,436	-43%	-$419K	﹤0.01%	890
2021 Q3	$1.18M	Hold	5,692	–	–	﹤0.01%	738
2021 Q2	$1.21M	Buy	+5,692	New	+$1.04M	﹤0.01%	741

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

KBC Group's NVAX Position: Q2 2026 in Review

KBC Group held its Novavax (NVAX) position steady in Q2 2026 at 4,746 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

KBC Group first reported a position in NVAX in Q2 2021 and has held it in 16 quarters since. The position peaked at $1.21M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

KBC Group held 4,746 shares of Novavax worth $45K as of Q2 2026.
KBC Group left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1736 holding.
KBC Group first reported a position in Novavax in Q2 2021 and has held it in 16 quarters since.
KBC Group's Novavax position peaked at $1.21M in Q2 2021.
267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.